Antifungal Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 244 of the 250 references it cites were found in a registry or an index.
Abstract
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This has been attributed to non-mycologic causes such as host factors, immune status, and/or pharmacologic issues8.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
In the citing paper
“it leaves the polyene amphotericin B, which is toxic8, as the only treatment option for these infections.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [8]
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · cited 2×
“…of cryptococcal meningitis 14 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg (Perfect et al. 2010), and, until recently, although clinical efficacy was clear with this strategy, formal PK/PD studies were lacking for this…”
BackgroundRex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,556
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“From a pharmacodynamic (PD) perspective, PK measures represent drug exposure with respect to the host, for example, translating a dose (i.e., mg/kg) to a drug exposure (e.g., area under the concentration curve, or AUC) (Drusano 2004).”
BackgroundPascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 1×
“Study from two phase 3 clinical trials of micafungin use in patients with candidemia or invasive candidiasis was recently used for PK/PD analysis (Andes et al. 2012).”
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 752
Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/514341 · Cited by 751
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727 · cited 1×
“Therefore, combination therapy may be particularly useful in treatment of the azole-resistant (Cyp51 mutant) Aspergillus infections that appear to be emergent in many parts of the world (Snelders et al. 2008).”
BackgroundAshbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 2×
“…phenomenon include protein kinase C (Wiederhold et al. 2005; Shields et al. 2011), the calcineurin pathway (Wiederhold et al. 2005; Shields et al. 2011), the high-osmolarity glycerol response pathway (Popolo et al. 2001), and heat shock protein 90 (Cowen and Lindquist 2005; Kaneko et al. 2009).”
BackgroundAmbrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638 · cited 1×
“Clinical studies in which echinocandin dose levels have been escalated have not identified a paradoxical effect (Pappas et al. 2007; Betts et al. 2009; Shields et al. 2011; Szilagyi et al. 2012; Andes et al. 2013; Elefanti et al. 2013).”
BackgroundCombination Antifungal Therapy for Invasive Aspergillosis
Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 596
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490 · cited 1×
“For treatment of a variety of invasive disease caused by a variety of fungal pathogens, optimal outcome is described with trough concentrations near 1 mg/ml (Andes et al. 2009).”
BackgroundSelf-citationPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484 · cited 1×
“Given the relatively wide therapeutic window with the echinocandins in patients, the potential to escalate drug doses could have important clinical implications given the recent emergence of drug-resistant C. glabrata infections (Pfaller et al. 2011b, 2012; Alexander et al. 2013).”
BackgroundArendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429 · cited 1×
“For intraocular and CNS infections fluconazole, voriconazole, flucytosine, and liposomal amphotericin B would be optimal from the PK standpoint (Utz 1975; Brammer et al. 1990; Purkins et al. 2002; Sun et al. 2009; Riddell et al. 2011; Schwartz et al. 2011).”
BackgroundTissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Method for antifungal disk diffusion susceptibility testing of yeasts : Approved guideline
Rex, J. H., & Clinical (2009) · Clinical and Laboratory Standards Institute eBooks · Cited by 422
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415 · cited 1×
“For intraocular and CNS infections fluconazole, voriconazole, flucytosine, and liposomal amphotericin B would be optimal from the PK standpoint (Utz 1975; Brammer et al. 1990; Purkins et al. 2002; Sun et al. 2009; Riddell et al. 2011; Schwartz et al. 2011).”
BackgroundVoriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Self-citationPfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377 · cited 1×
“Given the relatively wide therapeutic window with the echinocandins in patients, the potential to escalate drug doses could have important clinical implications given the recent emergence of drug-resistant C. glabrata infections (Pfaller et al. 2011b, 2012; Alexander et al. 2013).”
BackgroundGroll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373 · cited 5×
“…as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes et al. 2001, 2006; Vitale et al. 2003; Gavalda et al. 2005; Lewis et al. 2005; Wiederhold et al. 2006;…”
BackgroundInfluential(2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02086.x · Cited by 370
Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
Self-citationKurtz, M. B., Heath, I. B., Marrinan, J., Dreikorn, S., Onishi, J., & Douglas, C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 320 · cited 1×
“…Cold Spring Harb Perspect Med 2015;5:a019653 13 w w w .p er sp ec ti ve si n m ed ic in e. o rg rized that this lack of killing activity is related to the apparent limitation of drug activity concentrated at the hyphal tips based on morphology analysis following drug exposure (Kurtz et al. 1994).”
BackgroundTherapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Munro, C. A., Selvaggini, S., De Bruijn, I., Walker, L., Lenardon, M. D., Gerssen, B., Milne, S., Brown, A. J. P., & Gow, N. A. R. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05588.x · Cited by 309 · cited 1×
“Interestingly, all of these pathways seem to have a similar end product as they lead to elevated cell wall chitin content (Munro et al. 2007).”
BackgroundKontoyiannis, D. P., Hachem, R., Lewis, R. E., Rivero, G. A., Torres, H. A., Thornby, J., Champlin, R., Kantarjian, H., Bodey, G. P., & Raad, I. I. (2003) · Cancer · doi:10.1002/cncr.11479 · Cited by 287
Kirkpatrick, W. R., Perea, S., Coco, B. J., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2564-2568.2002 · Cited by 282 · cited 1×
“For example, a number of fixed-dose studies have suggested potential benefits of combination therapy (Kirkpatrick et al. 2002; Petraitis et al. 2003, 2009; Chandrasekar et al. 2004; MacCallum et al. 2005; van de Sande et al. 2009).”
BackgroundIn Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp
Arikan, S., Lozano-Chiu, M., Paetznick, V., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.245-247.2002 · Cited by 280
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274 · cited 2×
“Conversely, both ABLC and ABCDachieve much higherconcentrations in the intracellular space and in organs of the reticuloendothelial system (Janknegt et al. 1992).”
BackgroundPfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
In Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic Mice
Vogelman, B., Gudmundsson, S., Turnidge, J., Leggett, J., & Craig, W. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.2.287 · Cited by 259 · cited 2×
“This phenomenon was first observed and well described in bacteria (Eagle and Musselman 1949; Vogelman and Craig 1985; Craig and Vogelman 1987; Vogelman et al. 1988; Craig 1998) but has also been described in antifungal therapy (Fig.”
BackgroundPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 3×
“Although clinical PK/PD data sets are in general uncommon, there is a relatively large experience with fluconazole and voriconazole (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Pfaller et al. 2006; Pai et al. 2007; Rodrı́guez-Tudela et al. 2007; Baddley et al. 2008).”
ResultSelf-citationMeletiadis, J., Mouton, J. W., Meis, J. F. G. M., & Verweij, P. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.106-117.2003 · Cited by 253
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Self-citationProtein Binding: Do We Ever Learn?
Zeitlinger, M. A., Derendorf, H., Mouton, J. W., Cars, O., Craig, W. A., Andes, D., & Theuretzbacher, U. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01433-10 · Cited by 249 · cited 1×
“A relatively large number of antimicrobial treatment studies have shown that only free, non-protein-bound drug is pharmacologically active (Craig and Welling 1977; Zeitlinger et al. 2011).”
BackgroundSelf-citationRodvold, K. A., George, J. M., & Yoo, L. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594090-000000000-00000 · Cited by 246 · cited 1×
“However, ELF concentrations may be more relevant for prophylaxis as the organism must first colonize and infect the alveolar space, and prophylaxis studies in animal models using ELF concentrations are an emerging area of study (Rodvold et al. 2011).”
BackgroundKlepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H., & Pfaller, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1392 · Cited by 245
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., Karam, G. H., & Espinel-Ingroff, A. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90691-7 · Cited by 244 · cited 1×
“Toxicodynamic relationships, however, have been well established from clinical data (Kauffman and Frame 1977; Stamm et al. 1987; Francis and Walsh 1992; Pasqualotto et al. 2007; Smith and Andes 2008).”
BackgroundJang, S. H., Colangelo, P. M., & Gobburu, J. V. S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.64 · Cited by 239 · cited 1×
“Interestingly, TDM evaluation of both antifungals suggests that the PD target is roughly half of that needed for treatment of documented infection (Boogaerts et al. 1989; Jang et al. 2010; Campoli et al. 2013).”
BackgroundEriksson, U., Seifert, B., & Schaffner, A. (2001) · BMJ · doi:10.1136/bmj.322.7286.579 · Cited by 236 · cited 2×
“The latter toxicodynamic concept has also been further examined clinically with a suggestion of reduced renal toxicity when amphotericin B has been administered as a continuous infusion compared with once-daily bolus dosing (Eriksson et al. 2001; Imhof et al. 2003; Peleg and Woods 2004; Hall et al. 2005).”
BackgroundPetraitis, V., Petraitiene, R., Sarafandi, A. A., Kelaher, A. M., Lyman, C. A., Casler, H. E., Sein, T., Groll, A. H., Bacher, J., Avila, N. A., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/375420 · Cited by 233 · cited 2×
“Examples include measurement of fungal cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et…”
BackgroundFrancis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · cited 11×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundMethodInfluentialSelf-citationCRAIG, W. A., & VOGELMAN, B. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-900 · Cited by 228
Lewis, R. E. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.345 · Cited by 226
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226 · cited 2×
“In the context of antifungal drugs, the relevance of protein binding has been shown for both triazoles and echinocandins and will be elucidated in the following sections (Andes 2003a; Andes et al. 2010).”
BackgroundResultSelf-citationTroke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-10 · Cited by 218
Treatment of Endogenous Fungal Endophthalmitis: Focus on New Antifungal Agents
Riddell, J., Comer, G. M., & Kauffman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq204 · Cited by 217
Stevens, D. A., Espiritu, M., & Parmar, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3407-3411.2004 · Cited by 217 · cited 1×
“An interesting observation with the echinocandin class in experimental studies against Candida and Aspergillus is a concentration–effect ceiling, above which reduced activity and paradoxical growth are observed (Stevens et al. 2004, 2005, 2006; Clemons et al. 2006; Fortwendel et al. 2010).”
BackgroundCandida Urinary Tract Infections—Treatment
Fisher, J. F., Sobel, J. D., Kauffman, C. A., & Newman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir112 · Cited by 215 · cited 1×
“For example, only flucytosine and fluconazole achieve reliably therapeutic urine concentrations for treatment of lower urinary tract infections (Fisher et al. 2011).”
BackgroundBetts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598933 · Cited by 214 · cited 1×
“Clinical studies in which echinocandin dose levels have been escalated have not identified a paradoxical effect (Pappas et al. 2007; Betts et al. 2009; Shields et al. 2011; Szilagyi et al. 2012; Andes et al. 2013; Elefanti et al. 2013).”
BackgroundBowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3474-3481.2001 · Cited by 208 · cited 1×
“This nucleic acid assay provides a large dynamic range and has been shown to correlate well with mortality in animal models (Bowman et al. 2001; Francesconi et al. 2006; Sheppard et al. 2006; Vallor et al. 2008; Lengerova et al. 2012; Lepak et al. 2013a,b,c).”
MethodWiederhold, N. P., Kontoyiannis, D. P., Chi, J., Prince, R. A., Tam, V. H., & Lewis, R. E. (2004) · The Journal of Infectious Diseases · doi:10.1086/424465 · Cited by 207 · cited 4×
“Finally, as elucidated previously, Cmax/MIC is the predictive PD index for concentration-dependent drugs; however, whether there is evidence of prolonged PAFE, AUC/MIC and Cmax/MIC can both be predictive of efficacy.”
BackgroundInfluentialPenetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis
Savani, D. V., Perfect, J. R., Cobo, L. M., & Durack, D. T. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.1.6 · Cited by 202 · cited 1×
“Infection of the central nervous system (CNS), eye, and lower urinary tract are examples in which drug penetration and PK measurement at the site of infection has been shown to be relevant (Perfect et al. 1986; Savani et al. 1987; Groll et al. 2000; Gauthieret al. 2005).”
BackgroundWanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2520 · Cited by 202
Pharmacokinetics and Pharmacodynamics of Antimicrobials
Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/518137 · Cited by 194
Stevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193 · cited 1×
“An interesting observation with the echinocandin class in experimental studies against Candida and Aspergillus is a concentration–effect ceiling, above which reduced activity and paradoxical growth are observed (Stevens et al. 2004, 2005, 2006; Clemons et al. 2006; Fortwendel et al. 2010).”
BackgroundAndes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Self-citationBaddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G., & Moser, S. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00854-09 · Cited by 190
Self-citationAntifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L., & De Beule, K. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189 · cited 1×
“Interestingly, TDM evaluation of both antifungals suggests that the PD target is roughly half of that needed for treatment of documented infection (Boogaerts et al. 1989; Jang et al. 2010; Campoli et al. 2013).”
BackgroundSpellberg, B., Fu, Y., Edwards, J. E., & Ibrahim, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.830-832.2005 · Cited by 186 · cited 1×
“Combination therapy may be also a useful strategy for mucormycosis, and animal model data suggest utility of polyene/echinocandin therapy against Rhizopus oryzae (Spellberg et al. 2005; Ibrahim et al. 2008).”
BackgroundActivity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo
Rogers, T. E., & Galgiani, J. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.3.418 · Cited by 184
Perfect, J. R., Savani, D. V., & Durack, D. T. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.579 · Cited by 184 · cited 1×
“Infection of the central nervous system (CNS), eye, and lower urinary tract are examples in which drug penetration and PK measurement at the site of infection has been shown to be relevant (Perfect et al. 1986; Savani et al. 1987; Groll et al. 2000; Gauthieret al. 2005).”
BackgroundBerenguer, J., Allende, M. C., Lee, J. W., Garrett, K., Lyman, C., Ali, N. M., Bacher, J., Pizzo, P. A., & Walsh, T. J. (1995) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.152.3.7663787 · Cited by 183
Hope, W. W., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A. M., Hughes, J. E., Cotton, M. P., Bacher, J., Keirns, J. J., Buell, D., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/524063 · Cited by 183 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundPetraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.12-23.2002 · Cited by 182 · cited 1×
“…cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008;…”
BackgroundPetraitis, V., Petraitiene, R., Groll, A. H., Roussillon, K., Hemmings, M., Lyman, C. A., Sein, T., Bacher, J., Bekersky, I., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1857-1869.2002 · Cited by 182
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181 · cited 5×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialPharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180 · cited 4×
“Long PAFE effects have also been noted, with one study showing a PAFE of almost 1 d (.20 h) in a neutropenic mouse model (Turnidge et al. 1994; Ernst et al. 2000; Andes et al. 2001).”
BackgroundInfluentialSelf-citationCombination Echinocandin-Polyene Treatment of Murine Mucormycosis
Ibrahim, A. S., Gebremariam, T., Fu, Y., Edwards, J. E., & Spellberg, B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-07 · Cited by 180 · cited 1×
“Combination therapy may be also a useful strategy for mucormycosis, and animal model data suggest utility of polyene/echinocandin therapy against Rhizopus oryzae (Spellberg et al. 2005; Ibrahim et al. 2008).”
BackgroundPetraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179 · cited 1×
“…cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008;…”
BackgroundPharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177
Self-citationClancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 176 · cited 4×
“Although clinical PK/PD data sets are in general uncommon, there is a relatively large experience with fluconazole and voriconazole (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Pfaller et al. 2006; Pai et al. 2007; Rodrı́guez-Tudela et al. 2007; Baddley et al. 2008).”
BackgroundResultInfluentialIn Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis
Andes, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1179-1186.2003 · Cited by 169 · cited 2×
“In the context of antifungal drugs, the relevance of protein binding has been shown for both triazoles and echinocandins and will be elucidated in the following sections (Andes 2003a; Andes et al. 2010).”
BackgroundSelf-citationLouie, A., Deziel, M., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 164 · cited 10×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialAssociation of fluconazole pharmacodynamics with mortality in patients with candidemia
Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A., & Andes, D. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00116-08 · Cited by 162
Self-citationPai, M. P., Turpin, R. S., & Garey, K. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 159 · cited 2×
“Although clinical PK/PD data sets are in general uncommon, there is a relatively large experience with fluconazole and voriconazole (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Pfaller et al. 2006; Pai et al. 2007; Rodrı́guez-Tudela et al. 2007; Baddley et al. 2008).”
ResultActivity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis
Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., & Verweij, P. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3647-3650.2003 · Cited by 159 · cited 2×
“This may have been because of the fact that posaconazoleshowsmodestactivityagainstR.oryzae, the most common species of mucormycosis (Dannaoui et al. 2003; Barchiesi et al. 2007; Rodriguez et al. 2008; Ibrahim et al. 2009).”
BackgroundIn vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
Ernst, E. J., Klepser, M. E., Ernst, M. E., Messer, S. A., & Pfaller, M. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00130-8 · Cited by 158 · cited 1×
“However, the models provide an opportunity to accurately assess PD characteristics, such as the impact of concentration and can also be useful for estimating the PK/ PD target (Lewis et al. 1998, 2000; Ernst et al. 1999; Te Dorsthorst et al. 2013).”
BackgroundErnst, E. J., Roling, E. E., Petzold, C. R., Keele, D. J., & Klepser, M. E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3846-3853.2002 · Cited by 157 · cited 5×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundInfluentialProtein Binding of Antimicrobials
Craig, W. A., & Welling, P. G. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702040-00002 · Cited by 156
Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
Smith, J., & Andes, D. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318167d0e0 · Cited by 156 · cited 1×
“Toxicodynamic relationships, however, have been well established from clinical data (Kauffman and Frame 1977; Stamm et al. 1987; Francis and Walsh 1992; Pasqualotto et al. 2007; Smith and Andes 2008).”
BackgroundSelf-citationPharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154 · cited 2×
“The integration of concentration-independent action with prolonged PAFE would suggest that AUC/MIC is the PD index most closely associated with efficacy, which has been validated in dose-fractionation studies (Louie et al. 1998; Andes and van Ogtrop 1999; Andes et al. 2003a,b, 2004).”
BackgroundMethodFortwendel, J. R., Juvvadi, P. R., Perfect, B. Z., Rogg, L. E., Perfect, J. R., & Steinbach, W. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00854-09 · Cited by 153 · cited 1×
“An interesting observation with the echinocandin class in experimental studies against Candida and Aspergillus is a concentration–effect ceiling, above which reduced activity and paradoxical growth are observed (Stevens et al. 2004, 2005, 2006; Clemons et al. 2006; Fortwendel et al. 2010).”
BackgroundVogelman, B., & Craig, W. A. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.37 · Cited by 153
Bone Marrow Toxicity Associated with 5-Fluorocytosine Therapy
Kauffman, C. A., & Frame, P. T. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.2.244 · Cited by 150
Clemons, K. V., Espiritu, M., Parmar, R., & Stevens, D. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.4867-4875.2005 · Cited by 149
Amphotericin B lipid preparations: what are the differences?
Adler‐Moore, J., & Proffitt, R. T. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01979.x · Cited by 149
INFLUENCE OF BINDING ON THE PHARMACOLOGIC ACTIVITY OF ANTIBIOTICS
Kunin, C. M., Craig, W. A., Kornguth, M. L., & Monson, R. A. (1973) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1973.tb20483.x · Cited by 146 · cited 1×
“An additional PK measurement that warrants consideration is binding of drug to serum albumin (Kunin et al. 1973; Craig and Kunin 1976; Craig and Ebert 1989).”
BackgroundMukherjee, P. K., Mohamed, S., Chandra, J., Kuhn, D. M., Liu, S., Antar, O. S., Munyon, R., Mitchell, A. P., Andes, D. R., Chance, M. R., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00161-06 · Cited by 142 · cited 5×
“PD studies integrate drug PKs, including drug concentration over time, in vitro potency (MIC), and treatment efficacy (Craig 1998; Mukherjee et al. 2006; Drusano 2007).”
BackgroundInfluentialSelf-citationThe yeast cell-wall salvage pathway
Popolo, L., Gualtieri, T., & Ragni, E. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.111.121 · Cited by 142 · cited 2×
“2011), the high-osmolarity glycerol response pathway (Popolo et al. 2001), and heat shock protein 90 (Cowen and Lindquist 2005; Kaneko et al.”
BackgroundIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140 · cited 6×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundResultInfluentialSelf-citationGroll, A. H., Mickiene, D., Petraitienė, R., Petraitis, V., Lyman, C. A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2845-2855.2001 · Cited by 138 · cited 5×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialRodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137 · cited 4×
“Another study in oropharyngeal disease provides similar results, with 92% success noted in patients with a free-drug AUC/MIC of .25 and only 9% in those with a free-drug AUC/ MIC of ,25 (Rodrı́guez-Tudela et al. 2007).”
BackgroundResultInfluentialAndes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134 · cited 6×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundResultInfluentialSelf-citationWiederhold, N. P., Kontoyiannis, D. P., Prince, R. A., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5146-5148.2005 · Cited by 131 · cited 4×
“2011), the calcineurin pathway (Wiederhold et al. 2005; Shields et al. 2011), the high-osmolarity glycerol response pathway (Popolo et al.”
BackgroundInfluentialTHE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN
Eagle, H., & Musselman, A. D. (1949) · Journal of Bacteriology · doi:10.1128/jb.58.4.475-490.1949 · Cited by 129
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Population Pharmacokinetics of Micafungin in Neonates and Young Infants
Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., Walsh, T. J., Cohen-Wolkowiez, M., & Benjamin, D. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01679-09 · Cited by 129 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundResultLewis, R. E., Wiederhold, N. P., & Klepser, M. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.945-951.2005 · Cited by 129 · cited 3×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundResultHope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., Kasai, M., Mickiene, D., Sein, T., Peter, J., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/510535 · Cited by 128 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundGroll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3322-3327.2001 · Cited by 128 · cited 5×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialPharmacokinetics and Pharmacodynamics of Antifungals
Andes, D. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.007 · Cited by 124
Self-citationBradley, J. S., Dudley, M. N., & Drusano, G. L. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000094940.81959.14 · Cited by 122 · cited 1×
“When a PD target is validated, the most robust method to bridge predictions to humans is the use of Monte Carlo simulation to optimize dosing regimen design and identify the MIC ceiling (highest MIC) for which the PD target can be achieved (Bradley et al. 2003, 2010; Hope and Drusano 2009).”
MethodCNS pharmacokinetics of antifungal agents
Kethireddy, S., & Andes, D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425225.3.4.573 · Cited by 122
Self-citationAndes, D., Ambrose, P. G., Hammel, J. P., Van Wart, S. A., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119
Self-citationPetraitis, V., Petraitiene, R., Groll, A. H., Bell, A., Callender, D. P., Sein, T., Schaufele, R. L., McMillian, C. L., Bacher, J., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2898 · Cited by 118 · cited 1×
“Examples include measurement of fungal cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et…”
BackgroundImhof, A., Walter, R. B., & Schaffner, A. (2003) · Clinical Infectious Diseases · doi:10.1086/368312 · Cited by 118 · cited 2×
“The latter toxicodynamic concept has also been further examined clinically with a suggestion of reduced renal toxicity when amphotericin B has been administered as a continuous infusion compared with once-daily bolus dosing (Eriksson et al. 2001; Imhof et al. 2003; Peleg and Woods 2004; Hall et al. 2005).”
BackgroundArendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117
Andes, D., Safdar, N., Marchillo, K., & Conklin, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.674-684.2006 · Cited by 116 · cited 5×
“Dose-fractionation studies have found Cmax/MIC to be the PD index most predictive of efficacy (Andes et al. 2001, 2006).”
BackgroundResultInfluentialSelf-citationPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 2×
“Most other studies that have attempted to correlate dose, MIC, and outcome with AmB have been hampered by the very narrow MIC and dose range, making it very difficult to correlate the PD indices with outcome (Park et al. 2006).”
BackgroundMavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00931-09 · Cited by 112 · cited 2×
“The PD target free-drug AUC/MIC for Aspergillus associated with either ED50 or net stasis targets was only 1.7–11 (Mavridou et al. 2010a,b; Howard et al. 2011; Lepak et al. 2013a,c).”
BackgroundResultInfluentialMeletiadis, J., Verweij, P. E., Te Dorsthorst, D. T. A., Meis, J. F. G. M., & Mouton, J. W. (2005) · Medical Mycology · doi:10.1080/13693780410001731547 · Cited by 110
Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., Albano, E., Keirns, J. J., Buell, D. N., Gumbo, T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00398-07 · Cited by 110 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundMeletiadis, J., Mouton, J. W., Rodriguez-Tudela, J. L., Meis, J. F. G. M., & Verweij, P. E. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.470-472.2000 · Cited by 110
Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis
Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E., & Spellberg, B. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-08 · Cited by 108 · cited 3×
“This may have been because of the fact that posaconazoleshowsmodestactivityagainstR.oryzae, the most common species of mucormycosis (Dannaoui et al. 2003; Barchiesi et al. 2007; Rodriguez et al. 2008; Ibrahim et al. 2009).”
BackgroundResultMeletiadis, J., Petraitis, V., Petraitiene, R., Lin, P., Stergiopoulou, T., Kelaher, A. M., Sein, T., Schaufele, R. L., Bacher, J., & Walsh, T. J. (2006) · The Journal of Infectious Diseases · doi:10.1086/506617 · Cited by 108 · cited 2×
“…imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011;…”
BackgroundHoward, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., Majithiya, J. B., Warn, P. A., & Hope, W. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir023 · Cited by 106 · cited 4×
“The PD target free-drug AUC/MIC for Aspergillus associated with either ED50 or net stasis targets was only 1.7–11 (Mavridou et al. 2010a,b; Howard et al. 2011; Lepak et al. 2013a,c).”
BackgroundResultInfluentialThe postantibiotic effect of antifungal agents against common pathogenic yeasts
Turnidge, J. D., Gudmundsson, S., Vogelman, B., & Craig, W. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.1.83 · Cited by 105 · cited 7×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialWiederhold, N. P., Tam, V. H., Chi, J., Prince, R. A., Kontoyiannis, D. P., & Lewis, R. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.469-473.2006 · Cited by 105 · cited 3×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundResultSignificance of Serum Protein and Tissue Binding of Antimicrobial Agents
Craig, W. A., & Kunin, C. M. (1976) · Annual Review of Medicine · doi:10.1146/annurev.me.27.020176.001443 · Cited by 104
Studies of the paradoxical effect of caspofungin at high drug concentrations
Stevens, D. A., White, T. C., Perlin, D. S., & Selitrennikoff, C. P. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.10.006 · Cited by 103 · cited 2×
“For example, it has been noted in isolates that exhibit paradoxical growth to echinocandins that there is a compensatory up-regulation of the synthesis of the cell wall component chitin (Stevens et al. 2005; Bizerra et al. 2011).”
BackgroundRodríguez, M. M., Serena, C., Mariné, M., Pastor, F. J., & Guarro, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00628-08 · Cited by 103 · cited 2×
“This may have been because of the fact that posaconazoleshowsmodestactivityagainstR.oryzae, the most common species of mucormycosis (Dannaoui et al. 2003; Barchiesi et al. 2007; Rodriguez et al. 2008; Ibrahim et al. 2009).”
BackgroundHong, Y., Shaw, P. J., Nath, C. E., Yadav, S. P., Stephen, K. R., Earl, J. W., & McLachlan, A. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.935-942.2006 · Cited by 102 · cited 2×
“Clinical Implications Clinical PD studies of amphotericin B for which PK, MIC, and outcome data are available are limited to a single pediatric cohort (Hong et al. 2006).”
BackgroundSchwartz, S., Reisman, A. L., & Troke, P. F. (2011) · Infection · doi:10.1007/s15010-011-0108-6 · Cited by 101 · cited 1×
“For intraocular and CNS infections fluconazole, voriconazole, flucytosine, and liposomal amphotericin B would be optimal from the PK standpoint (Utz 1975; Brammer et al. 1990; Purkins et al. 2002; Sun et al. 2009; Riddell et al. 2011; Schwartz et al. 2011).”
BackgroundLewis, R. E., Lund, B. C., Klepser, M. E., Ernst, E. J., & Pfaller, M. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1382 · Cited by 101 · cited 1×
“However, the models provide an opportunity to accurately assess PD characteristics, such as the impact of concentration and can also be useful for estimating the PK/ PD target (Lewis et al. 1998, 2000; Ernst et al. 1999; Te Dorsthorst et al. 2013).”
BackgroundGumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., & Louie, A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-06 · Cited by 101 · cited 3×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundMethodIn vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1187-1192.2003 · Cited by 100 · cited 12×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundMethodInfluentialSelf-citationBrock, M., Jouvion, G., Droin-Bergère, S., Dussurget, O., Nicola, M.-A., & Ibrahim-Granet, O. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.01288-08 · Cited by 99 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
BackgroundGauthier, G. M., Nork, T. M., Prince, R., & Andes, D. (2005) · Clinical Infectious Diseases · doi:10.1086/431761 · Cited by 99
Self-citationAssessment of the Paradoxical Effect of Caspofungin in Therapy of Candidiasis
Clemons, K. V., Espiritu, M., Parmar, R., & Stevens, D. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1293-1297.2006 · Cited by 99 · cited 1×
“An interesting observation with the echinocandin class in experimental studies against Candida and Aspergillus is a concentration–effect ceiling, above which reduced activity and paradoxical growth are observed (Stevens et al. 2004, 2005, 2006; Clemons et al. 2006; Fortwendel et al. 2010).”
BackgroundIn vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1193-1199.2003 · Cited by 98 · cited 11×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundMethodInfluentialSelf-citationAndes, D., & van Ogtrop, M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 97
Self-citationPetraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., Cotton, M. P., Stergiopoulou, T., Kasai, M., Francesconi, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00329-09 · Cited by 94 · cited 2×
“Examples include measurement of fungal cell wall component (galactomannan and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et…”
BackgroundBizerra, F. C., Melo, A. S. A., Katchburian, E., Freymüller, E., Straus, A. H., Takahashi, H. K., & Colombo, A. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-10 · Cited by 91 · cited 1×
“For example, it has been noted in isolates that exhibit paradoxical growth to echinocandins that there is a compensatory up-regulation of the synthesis of the cell wall component chitin (Stevens et al. 2005; Bizerra et al. 2011).”
BackgroundLepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01355-13 · Cited by 88
Self-citationWarn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., & Hope, W. W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01601-08 · Cited by 86 · cited 1×
“Concentration-escalation studies have consistently shown concentration-independent action against Candida species, with maximal growth inhibition at concentrations near the MIC (Ernst et al. 1998, 2002b; Louie et al. 1998; Andes and van Ogtrop 1999; Andes et al. 2003a,b, 2004; Warn et al. 2009).”
BackgroundMavridou, E., Bruggemann, R. J. M., Melchers, W. J. G., Verweij, P. E., & Mouton, J. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00606-10 · Cited by 85 · cited 2×
“The PD target free-drug AUC/MIC for Aspergillus associated with either ED50 or net stasis targets was only 1.7–11 (Mavridou et al. 2010a,b; Howard et al. 2011; Lepak et al. 2013a,c).”
BackgroundResultInfluentialLee, S.-C., Fung, C.-P., Huang, J.-S., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L.-C., & Shieh, W.-B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81 · cited 2×
“In aggregate, the individual studies include fluconazole drug exposure (PK/PD) for .600 patients with invasive candidiasis (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Baddley et al. 2008).”
BackgroundResultProtein Binding and Its Significance in Antibacterial Therapy
Craig, W. A., & Ebert, S. C. (1989) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30278-6 · Cited by 78
Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., Hope, W. W., Shea, Y. R., Bacher, J., & Walsh, T. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.02693-05 · Cited by 78 · cited 2×
“…and b-glucan), pulmonary imaging, histopathology, and lung weight (Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al.…”
BackgroundMethodCompartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations
Groll, A. H., Lyman, C. A., Petraitis, V., Petraitiene, R., Armstrong, D., Mickiene, D., Alfaro, R. M., Schaufele, R. L., Sein, T., Bacher, J., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-06 · Cited by 77 · cited 2×
“There are numerous additional analyses that include PK and outcome (Janknegt et al. 1992; Groll et al. 2006; Lewis et al. 2007; Bradley et al. 2010).”
BackgroundAndes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., & Lincoln, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01053-05 · Cited by 76 · cited 15×
“Most other studies that have attempted to correlate dose, MIC, and outcome with AmB have been hampered by the very narrow MIC and dose range, making it very difficult to correlate the PD indices with outcome (Park et al. 2006).”
BackgroundInfluentialSelf-citationClancy, C. J., Huang, H., Cheng, S., Derendorf, H., & Nguyen, M. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-06 · Cited by 73
Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis
MacCallum, D. M., Whyte, J. A., & Odds, F. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3697-3701.2005 · Cited by 73 · cited 1×
“For example, a number of fixed-dose studies have suggested potential benefits of combination therapy (Kirkpatrick et al. 2002; Petraitis et al. 2003, 2009; Chandrasekar et al. 2004; MacCallum et al. 2005; van de Sande et al. 2009).”
BackgroundPeleg, A. Y., & Woods, M. L. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh403 · Cited by 73
Louie, A., Liu, W., Miller, D. A., Sucke, A. C., Liu, Q.-F., Drusano, G. L., Mayers, M., & Miller, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2831 · Cited by 72
Van t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Vallor, A. C., Kirkpatrick, W. R., Najvar, L. K., Bocanegra, R. A., Kinney, M. C., Fothergill, A. W., Herrera, M., Wickes, B. L., Graybill, J. R., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-08 · Cited by 71 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
MethodLepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01279-12 · Cited by 71 · cited 7×
“An additional invivo study has incorporated a wide dose-ranging combination therapy design for invasive aspergillosis (Lepak et al. 2013b).”
BackgroundMethodResultInfluentialSelf-citationFlucytosine therapeutic monitoring: 15 years experience from the UK
Pasqualotto, A. C., Howard, S. J., Moore, C. B., & Denning, D. W. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl550 · Cited by 71 · cited 1×
“Toxicodynamic relationships, however, have been well established from clinical data (Kauffman and Frame 1977; Stamm et al. 1987; Francis and Walsh 1992; Pasqualotto et al. 2007; Smith and Andes 2008).”
BackgroundGumbo, T., Drusano, G. L., Liu, W., Ma, L., Deziel, M. R., Drusano, M. F., & Louie, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00507-06 · Cited by 71 · cited 5×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundInfluentialLewis, R. E., Liao, G., Hou, J., Chamilos, G., Prince, R. A., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01449-06 · Cited by 69 · cited 2×
“There are numerous additional analyses that include PK and outcome (Janknegt et al. 1992; Groll et al. 2006; Lewis et al. 2007; Bradley et al. 2010).”
BackgroundSeyedmousavi, S., Bruggemann, R. J. M., Melchers, W. J. G., Rijs, A. J. M. M., Verweij, P. E., & Mouton, J. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks402 · Cited by 69 · cited 3×
“The PD studies from preclinical models would suggest that this potential toxicodynamic benefit may negatively impact therapeutic efficacy based on lower Cmax/MIC attainment with a continuous-infusion dosing strategy (Seyedmousavi et al. 2013b).”
BackgroundSheppard, D. C., Marr, K. A., Fredricks, D. N., Chiang, L., Doedt, T., & Filler, S. G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01349.x · Cited by 68
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism.
Snelders, E., Lee, H., Kuijpers, J., Rijs, A., Varga, J., Samson, R., Mellado, E., Donders, A., Melchers, W., & Verweij, P. (2008) · SciVee · doi:10.4016/8254.01 · Cited by 67
Meletiadis, J., Stergiopoulou, T., O'Shaughnessy, E. M., Peter, J., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00873-06 · Cited by 66
Shields, R. K., Nguyen, M. H., Du, C., Press, E., Cheng, S., & Clancy, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-10 · Cited by 65 · cited 6×
“A confirmatory study design showed abolition of the paradoxical effect following the addition of a chitin synthase inhibitor to echinocandin therapy (Shields et al. 2011; Szilagyi et al. 2012).”
BackgroundInfluentialLepak, A. J., Marchillo, K., VanHecker, J., Diekema, D., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01354-13 · Cited by 65 · cited 7×
“An additional invivo study has incorporated a wide dose-ranging combination therapy design for invasive aspergillosis (Lepak et al. 2013b).”
BackgroundMethodResultInfluentialSelf-citationSun, H., Alexander, B. D., Lortholary, O., Dromer, F., Forrest, G. N., Lyon, G. M., Somani, J., Gupta, K. L., Busto, R. D., Pruett, T. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/647948 · Cited by 64 · cited 1×
“For intraocular and CNS infections fluconazole, voriconazole, flucytosine, and liposomal amphotericin B would be optimal from the PK standpoint (Utz 1975; Brammer et al. 1990; Purkins et al. 2002; Sun et al. 2009; Riddell et al. 2011; Schwartz et al. 2011).”
BackgroundLewis, R. E., Ben-Ami, R., Best, L., Albert, N., Walsh, T. J., & Kontoyiannis, D. P. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jis767 · Cited by 63 · cited 1×
“However, escalation of posaconazole exposure has shown efficacy, and combination with tacrolimus also showed enhanced effect (Rodriguez et al. 2010; Lewis et al. 2013).”
BackgroundLewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn069 · Cited by 63 · cited 1×
“…also exhibit activity against Aspergillus species, and animal model studies show similar PK/PD characteristics including concentration-dependent effects and efficacy linked to AUC/MIC and Cmax/MIC (Wiederhold et al. 2004; Clemons and Stevens 2006; Lewis et al. 2008, 2011; Lepak et al. 2013b).”
BackgroundCombination antifungal therapy: a critical review of the evidence
Ostrosky-Zeichner, L. L. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01983.x · Cited by 61
Chandrasekar, P. H., Cutright, J. L., & Manavathu, E. K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00958.x · Cited by 60 · cited 1×
“For example, a number of fixed-dose studies have suggested potential benefits of combination therapy (Kirkpatrick et al. 2002; Petraitis et al. 2003, 2009; Chandrasekar et al. 2004; MacCallum et al. 2005; van de Sande et al. 2009).”
BackgroundO'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., Felton, T. W., Schwartz, J. A., Neely, M. N., Harrison, T. S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit164 · Cited by 60 · cited 2×
“Similar PK/PD studies for Cryptococcus species are limited but do suggest that the current human regimen is sufficient for stasis (O’Connor et al. 2013).”
BackgroundSudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., Gregson, L., Warn, P. A., Felton, T. W., Perfect, J. R., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00216-13 · Cited by 59 · cited 1×
“An additional study has examined the fluconazole PD target in a murine cryptococcal meningitis model (Sudan et al. 2013).”
BackgroundGaliger, C., Brock, M., Jouvion, G., Savers, A., Parlato, M., & Ibrahim-Granet, O. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01660-12 · Cited by 59 · cited 2×
“…(Petraitis et al. 1998, 2002, 2003, 2006, 2009; Petraitiene et al. 2001, 2002; Francesconi et al. 2006; Meletiadis et al. 2006; Sheppard et al. 2006; Brock et al. 2008; Vallor et al. 2008; Wiederhold et al. 2008; Walsh et al. 2009; Howard et al. 2011; Lengerova et al. 2012; Galiger et al. 2013).”
BackgroundFujihara, N., Saito, T., Kudo, T., Iinuma, Y., Ichiyama, S., & Takakura, S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1128-2 · Cited by 58 · cited 2×
“In aggregate, the individual studies include fluconazole drug exposure (PK/PD) for .600 patients with invasive candidiasis (Rex et al. 1997; Lee et al. 2000; Takakura et al. 2004; Clancy et al. 2005; Baddley et al. 2008).”
BackgroundResultChryssanthou, E., & Cuenca‐Estrella, M. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01419.x · Cited by 56 · cited 1×
“MIC end points and time at which they are read can differ from drug to drug and between standardized methodologies (Chryssanthou and Cuenca-Estrella 2006; Pfaller and Diekema 2012).”
BackgroundErnst, E. J., Yodoi, K., Roling, E. E., & Klepser, M. E. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.578-581.2002 · Cited by 56 · cited 6×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundInfluentialPetraitis, V., Petraitiene, R., Groll, A. H., Sein, T., Schaufele, R. L., Lyman, C. A., Francesconi, A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.471-479.2001 · Cited by 53 · cited 1×
“…and animal model studies of invasive candidiasis have revealed pronounced concentration-dependent killing effects with prolonged PAFEs (Groll et al. 2001; Petraitis et al. 2001, 2002; Ernst et al. 2002a; Andes et al. 2003c, 2008a,b; Louie et al. 2005; Gumbo et al. 2006, 2007; Hope et al. 2008).”
BackgroundDenning, D. W., & Warn, P. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2592 · Cited by 53 · cited 2×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundLouie, A., Banerjee, P., Drusano, G. L., Shayegani, M., & Miller, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2841 · Cited by 53
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
Hope, W. W., & Drusano, G. L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02913.x · Cited by 52
Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., Arendrup, M. C., Warn, P. A., Perlin, D. S., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01686-10 · Cited by 52
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis
Clemons, K. V., & Stevens, D. A. (2006) · Medical Mycology · doi:10.1080/13693780500148350 · Cited by 51
Walsh, T. J., Lee, J. W., Kelly, P., Bacher, J., Lecciones, J., Thomas, V, Lyman, C., Coleman, D., Gordee, R., & Pizzo, P. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.7.1321 · Cited by 50 · cited 17×
“For example, triazoles exhibit prolonged PAFEs, and it has been shown that AUC/MIC is the optimal predictive index (Turnidge et al. 1994; Andes and van Ogtrop 1999; Ernst et al. 2000; Andes et al. 2003a,b, 2004), whereas flucytosine exhibits little PAFE, and in this case %T .”
BackgroundInfluentialCampoli, P., Perlin, D. S., Kristof, A. S., White, T. C., Filler, S. G., & Sheppard, D. C. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit358 · Cited by 50 · cited 1×
“Interestingly, TDM evaluation of both antifungals suggests that the PD target is roughly half of that needed for treatment of documented infection (Boogaerts et al. 1989; Jang et al. 2010; Campoli et al. 2013).”
BackgroundPharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation
Bradley, J. S., Merali, S. J., Forrest, A., & Bhavnani, S. M. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f42a53 · Cited by 49 · cited 2×
“When a PD target is validated, the most robust method to bridge predictions to humans is the use of Monte Carlo simulation to optimize dosing regimen design and identify the MIC ceiling (highest MIC) for which the PD target can be achieved (Bradley et al. 2003, 2010; Hope and Drusano 2009).”
BackgroundMethodClinical Practice: Combination Antifungal Therapy for Mold Infections: Much Ado about Nothing?
Vazquez, J. A. (2008) · Clinical Infectious Diseases · doi:10.1086/588475 · Cited by 49 · cited 1×
“A number of in vitro studies have examined combinations of polyene/azole, polyene/echinocandin, and azole/echinocandin (Vazquez 2008; Seyedmousavi et al. 2013c,d).”
BackgroundHope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., Walsh, T. J., Drusano, G. L., & Denning, D. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00369-06 · Cited by 49 · cited 3×
“…of escalating concentrations of flucytosine on efficacy 10 Cite this article as Cold Spring Harb Perspect Med 2015;5:a019653 w w w .p er sp ec ti ve si n m ed ic in e. o rg against Candida (Turnidge et al. 1994; Andes and van Ogtrop 2000; Lewis et al. 2000; Ernst et al. 2002b; Hope et al. 2006).”
BackgroundHoward, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., Perlin, D. S., Warn, P. A., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00621-11 · Cited by 48 · cited 3×
“The PD target free-drug AUC/MIC for Aspergillus associated with either ED50 or net stasis targets was only 1.7–11 (Mavridou et al. 2010a,b; Howard et al. 2011; Lepak et al. 2013a,c).”
BackgroundResultInfluentialIn vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods☆
Lewis, R. E., Klepser, M. E., & Pfaller, M. A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00125-x · Cited by 47 · cited 3×
“However, the models provide an opportunity to accurately assess PD characteristics, such as the impact of concentration and can also be useful for estimating the PK/ PD target (Lewis et al. 1998, 2000; Ernst et al. 1999; Te Dorsthorst et al. 2013).”
Backgroundvan de Sande, W. W. J., Mathot, R. A. A., ten Kate, M. T., van Vianen, W., Tavakol, M., Rijnders, B. J. A., & Bakker-Woudenberg, I. A. J. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-08 · Cited by 45
Clinical utility of antifungal pharmacokinetics and pharmacodynamics
Andes, D. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00005 · Cited by 45 · cited 2×
“This has been shown to be true for candidiasis, including mucocutaneous and invasive/disseminated disease (Andes 2004; Mukherjee et al. 2006).”
BackgroundSelf-citationSeyedmousavi, S., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02226-12 · Cited by 45 · cited 4×
“In vitro and animal model PD time-kill studies against Candida and filamentous fungi have shown concentration-dependent action as drug dose is escalated multiple times above the MIC (Turnidge et al. 1994; Kelpser et al. 1997; Denning and Warn 1999; Ernst et al. 2000, 2002b; Groll et al. 2000; Warn et al. 2000; Andes e…”
BackgroundInfluentialCombination chemotherapy for the treatment of invasive infections by Scedosporium prolificans
Meletiadis, J., Mouton, J. W., Meis, J. F. G. M., & Verweij, P. E. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00089.x · Cited by 44
Posaconazole Prophylaxis in Experimental Systemic Zygomycosis
Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A. W., Pisa, E., Giannini, D., Rinaldi, M. G., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00969-06 · Cited by 44 · cited 2×
“This may have been because of the fact that posaconazoleshowsmodestactivityagainstR.oryzae, the most common species of mucormycosis (Dannaoui et al. 2003; Barchiesi et al. 2007; Rodriguez et al. 2008; Ibrahim et al. 2009).”
BackgroundJeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J. B., Lass-Flörl, C., Cuenca-Estrella, M., Arendrup, M. C., Warn, P. A., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis372 · Cited by 42
Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., Goodwin, J., Petraitiene, R., Petraitis, V., Cohen-Wolkowiez, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05826-11 · Cited by 41 · cited 2×
“…neonates, and for certain infections in which the study of different dosing regimens is impractical based on the number of possible regimens or unethical because the study would include suboptimal regimens that cannot be justified (Hope et al. 2007b,2008, 2010; Ikawa et al. 2009; Warn et al. 2012).”
BackgroundResultLepak, A., Castanheira, M., Diekema, D., Pfaller, M., & Andes, D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-12 · Cited by 41 · cited 2×
“Animal model PK/PD studies with wildtype susceptible and drug-resistant C. glabrata clinical isolates resulting from a variety of Fks mutations found that a similar AUC/MIC is needed for efficacy (Lepak et al. 2012).”
BackgroundSelf-citationRodríguez, M. M., Pastor, F. J., Sutton, D. A., Calvo, E., Fothergill, A. W., Salas, V., Rinaldi, M. G., & Guarro, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01463-09 · Cited by 41 · cited 1×
“However, escalation of posaconazole exposure has shown efficacy, and combination with tacrolimus also showed enhanced effect (Rodriguez et al. 2010; Lewis et al. 2013).”
Background
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 176
“Readers are referred to excellent reviews on these topics [50,51].”
BackgroundIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144
“and interact with other drugs such as chemotherapy agents and immunosuppressants (4).”
BackgroundDefining the frontiers between antifungal resistance, tolerance and the concept of persistence
Delarze, E., & Sanglard, D. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.001 · Cited by 118
Metadata
- Authors
- Lepak, A. J., & Andes, D. R.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-11-10
- Volume
- 5
- Issue
- 5
- Pages
- a019653-a019653
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC4448584
- OpenAlex
- W2106743979
- Cited by
- 134
- References
- 250
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 14 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 17 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 2 · 2015: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, pharmacokinetics, pharmacodynamics, pharmacokinetic-pharmacodynamic modeling, polyenes, 5-fluorocytosine, azoles, echinocandins, dosing regimen, susceptibility breakpoints, combination antifungal therapy, drug toxicity
- MeSH terms
- Animals, Antifungal Agents, Disease Models, Animal, Flucytosine, Humans, Mycoses, Polyenes, Rabbits, Triazoles, Mice, Rats, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.